Leading Biopharmaceutical Researchers to Showcase the New Era of Medicine on Capitol Hill
Congressional fly-in will spotlight the critical role of continued biopharmaceutical R&D to fuel the next generation of treatments and cures
WASHINGTON, D.C. (November 2, 2017) — The Pharmaceutical Research and Manufacturers of America (PhRMA) is bringing more than 50 scientists and researchers from America’s biopharmaceutical companies to meet with policymakers and senior staff today on Capitol Hill. The meetings will allow the scientists and researchers to discuss with lawmakers their work in tackling the most complex and devastating health conditions.
The group will highlight the innovative new medicines being developed to treat conditions including cancer, neurological disorders, cardiovascular disease, rare diseases and many others. The researchers will also discuss their work in clinical trials and the promising advancements in the pipeline for millions of patients.
“There is no better voice to deliver the story of innovation than the biopharmaceutical researchers who persevere every day in their quest to find new treatments and cures,” said Stephen J. Ubl, president and CEO of PhRMA. “The science has never been more promising and it’s critical we have policies that not only sustain the remarkable progress we have seen, but also foster the next generation of therapies to fight disease.”
Today’s researcher fly-in is part of the GOBOLDLY campaign, a multi-year national effort showcasing the work of biopharmaceutical researchers devoted to discovering and developing medicines that enable patients to live longer, healthier lives.
To learn more about the GOBOLDLY campaign, please visit: www.GoBoldly.com
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $65.5 billion in 2016 alone.